What is Ligand Pharmaceuticals Incorpor (LGND)?
Ligand Pharmaceuticals Incorpor is a biopharmaceutical company focused on developing or acquiring technologies that aid in drug discovery and development. The company specializes in creating or licensing drug candidates and partnering with other pharmaceutical firms to advance these compounds through clinical development. Ligand Pharmaceuticals operates a portfolio of technologies and proprietary platforms designed to enhance the efficiency of drug development processes. It collaborates with various partners across the pharmaceutical and biotechnology sectors to generate revenue through licensing agreements, milestone payments, and royalties. The company’s business model emphasizes leveraging its expertise and intellectual property to facilitate the commercialization of novel therapeutics. Ligand Pharmaceuticals is involved in multiple therapeutic areas and supports the development of drugs targeting diverse medical conditions. Its operations include research, licensing, and strategic partnerships within the pharmaceutical industry.
Ligand Pharmaceuticals Incorpor Stock Price Today: Live Overview
The price today is shaped by Ligand Pharmaceuticals Incorpor's trading, now at $203.77. Its daily range has spanned from $199.65 to $212.15, with a percentage change of 0%.
FAQ: Ligand Pharmaceuticals Incorpor (LGND)
What is the current price of LGND stock?
Ligand Pharmaceuticals Incorpor's price is $203.77.
Does LGND pay dividends?
Ligand Pharmaceuticals Incorpor pays dividends via cash distributions (if applicable).
Does LGND have a formal corporate presence or regional headquarters in the UAE?
Ligand Pharmaceuticals Incorpor operates in the UAE through partners and distributors without a direct regional office.
What is LGND best known for?
Ligand Pharmaceuticals Incorpor is most famous for its drug discovery and development technologies.
What assets are typically shown together with LGND?
Commonly shown alongside LGND: Compugen Ltd., IQVIA Holdings Inc., Etoro Group ltd
Latest shares articles



